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Dear Editor,
Quinolones were first introduced in 1962, and their
excellent oral absorption, good tissue distribution in tissue,
and urinary concentrations, which exceed the minimum
inhibitory concentration for many common pathogens,
popularized their use in routine clinical practice.
Structural modifications of quinolones resulted in improved
pharmacokinetics, with a longer elimination half-life, which
permitted once-daily dosing and improved tissue penetra-
tion. For this reason and many others, fourth generation
compounds, such as moxifloxacin, are increasingly being
prescribed (1,2).
Moxifloxacin is licensed to treat acute bacterial sinusitis,
acute bacterial exacerbation of chronic bronchitis, commu-
nity acquired pneumonia, complicated and uncomplicated
skin and skin structure infections, and complicated intra-
abdominal infections. In 2007, moxifloxacin ranked 140th
among the top 200 drugs prescribed in the United States,
and it has proven to be a blockbuster drug, generating
billions of dollars in revenue. In 2007 alone, AveloxH
generated $697.3 million in sales worldwide (2).
In ophthalmology, moxifloxacin is widely prescribed as
eye drops to treat infectious keratitis and as a postoperative
prophylactic regimen during cataract surgery. It is also
injected intraocularly to prevent and treat intraocular
infections (3).
Acute depigmentation of the iris is a new clinical
condition that is characterized by an acute onset of pigment
dispersion in the anterior chamber, depigmentation and
discoloration of the iris stroma, pigment deposition in the
anterior chamber angle, and positive transillumination (4).
Systemic moxifloxacin treatment has been associated with
this condition (5).
Several types of iris changes, such as positive transillu-
mination, dyschoria, and depigmentation, have been
reported; anterior chamber reaction and anterior uveitis-
like syndrome have also been observed in some cases.
Patients usually have bilateral asymmetrical involvement.
Atonic pupils with distorted margins and occasionally
ocular hypertension were described by Tugal-Tutkun et al.
(4,5).
This assemblage of clinical findings is distinct from other
known causes of iris depigmentation and pigment disper-
sion, such as Fuchs’ uveitis syndrome, viral iridocyclitis,
Horner’s syndrome, Vogt-Koyanagi-Harada disease, and
pigment dispersion syndrome (4,6,7,8).
Acute depigmentation of the iris may be more common
than expected in many countries, including Brazil.
Therefore, it is important to detect and correctly diagnose
it. Below, we describe three recent cases of acute depig-
mentation of the iris.
THMZ, a 70-year-old white female with diabetes and
hypothyroidism, presented with photophobia for 15 days.
Her eyes were examined twice in the previous 2 years and
found normal. A current exam revealed best corrected
visual acuity of 20/20 OU. The IOP was 14 mmHg OU.
Anterior biomicroscopy showed positive iris transillumina-
tion in both eyes and a heavily pigmented anterior chamber
angle. No anterior chamber reaction or signs of inflamma-
tion were noted. The lens was clear OU. The fundoscopic
findings were unremarkable. The patient had been pre-
scribed a 15-day course of systemic moxifloxacin (AvaloxH)
for pneumonia 3 months before the onset of symptoms.
TF, a 32-year-old white female complained of low visual
acuity and photophobia in the left eye for 10 weeks and the
right eye for 8 weeks. The exam revealed visual acuity of
20/20 OU. Biomicroscopy showed bilateral positive iris
transillumination, dense atrophy, and dyschoria. The lens
was clear OU. The IOP was 16 mmHg OU, and the
fundoscopic findings were normal. No signs of active ocular
inflammation were noted. The patient had been extensively
examined for uveitis and pigmentary glaucoma, with
negative results. She had been prescribed systemic moxi-
floxacin (AvaloxH) for pneumonia 2 months before the onset
of symptoms.
RMP, a 26-year-old male, also had a previous history of
systemic moxifloxacin use for upper respiratory infection 3
months before the onset of symptoms. An exam revealed
visual acuity of 20/20 OD and 20/30 OS. Biomicroscopy
showed a normal right eye, positive transillumination and
dyschoria in the left eye, and a moderate anterior chamber
reaction. The lens was clear OU. The IOP was 12 mmHg
OU, and the fundoscopic evaluation was normal. No keratic
precipitates were noted, and the condition was resolved
with a short course of mild steroids.
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Our cases indicated that these Brazilian patients had
unilateral or bilateral asymmetrical involvement, transillu-
mination defects, and dyschoria. Photophobia was the main
complaint. The first two patients were examined after
complaining of photophobia. We presume that iris transil-
lumination was already present, although we do not know
whether the patients had prior inflammation signs. The
third patient was observed earlier in the course of the
disease, and signs of mild inflammation were observed. All
patients were treated with mild topical steroids, and their
symptoms improved, although the clinical signs remained
stable.
The differential diagnosis involves inflammatory and
non-inflammatory entities; in most cases, the etiology and
physiopathology mechanisms leading to the iris changes are
unclear. Herpetic iridocyclitis without associated keratitis is
a distinct entity that is characterized by unilateral recur-
rences in the same eye, sectoral or patchy atrophy of the iris,
and an acute IOP increase (4). Sectoral iris atrophy is rarely
observed in immunocompetent patients with CMV anterior
uveitis. Sectoral atrophy resulting from ischemic necrosis of
the iris and loss of function of the sphincter muscle may
cause pupillary distortion, which is sometimes associated
with iris spiraling. Transillumination caused by the loss of
iris pigment epithelium may be observed in the absence of
apparent iris stromal atrophy. Posterior synechiae develop
in more than 50% of cases (5).
Fuchs’ uveitis syndrome is another unilateral uveitic
entity that is associated with diffuse atrophy of the iris with
or without heterochromia. One of the early diagnostic
features is iris stromal smoothing, with loss of the normal
corrugated texture. Iris stroma does not assume a granular
appearance in Fuchs’ uveitis syndrome, and atrophy, with
or without hypochromia, is diffuse (6,7).
The pharmacokinetics of moxifloxacin demonstrate that
the aqueous concentration is higher than the vitreous
concentration upon topical administration. However, the
aqueous concentration is similar to that in the vitreous when
moxifloxacin is taken orally. Knape et al. observed that only
phakic patients have been reported with acute depigmenta-
tion of the iris associated with moxifloxacin, most likely
because the posterior-to-anterior clearance may be impaired
or perhaps posterior synechiae trap the drug in the posterior
chamber. This explanation might be the reason why only
systemic and not topical moxifloxacin causes this condition
(9).
All physicians, not just ophthalmologists, should be
aware of this entity. The potential associations should be
better understood because it is still unclear whether this
disease represents an adverse effect of fluoroquinolone use
or the sequelae of a systemic infectious disease.
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Figure 1 - Right and left eye anterior segment photograph.
Positive iris transillumination.
Figure 2 - Bilateral iris depigmentation and dyschoria.
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